Phase II Study of Gefitinib in Patients with Relapsed or Persistent Ovarian or Primary Peritoneal Carcinoma and Evaluation of Epidermal Growth Factor Receptor Mutations and Immunohistochemical Expression: A Gynecologic Oncology Group Study

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Clinical Cancer Research

• Publication date

  2005-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-05-0462PMID 16061871
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

  2005cited by this paper
• Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-anilinoquinazolines

  2005cited by this paper
• Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer.

  2005cited by this paper
• Cancer Statistics, 2005

  2005cited by this paper
• EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

  2005cited by this paper
• 'Targeting' the epidermal growth factor receptor tyrosine kinase with gefitinib (Iressa) in non-small cell lung cancer (NSCLC).

  2004cited by this paper
• EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.

  2004cited by this paper
• EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

  2004cited by this paper
• United States Food and Drug Administration Drug Approval Summary

  2004cited by this paper
• Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

  2004cited by this paper
• Mutations of the Epidermal Growth Factor Receptor Gene in Lung Cancer

  2004cited by this paper
• Mutations and addiction to EGFR: the Achilles 'heal' of lung cancers?

  2004cited by this paper
• Anticancer drugs: To the rescue?

  2004cited by this paper
• Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

  2004cited by this paper
• Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study.

  2004cited by this paper
• Dendritic cell-based cancer immunotherapy.

  2003cited by this paper
• Developing inhibitors of the epidermal growth factor receptor for cancer treatment.

  2003cited by this paper
• Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

  2003cited by this paper
• Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.

  2003cited by this paper
• Development of the epidermal growth factor receptor inhibitor OSI-774.

  2003cited by this paper
• Gefitinib Therapy for Advanced Non–Small-Cell Lung Cancer

  2003cited by this paper
• Expression of constitutively activated EGFRvlll in non‐small cell lung cancer

  2003cited by this paper
• ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy.

  2002cited by this paper
• The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells.

  2001cited by this paper
• Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.

  2001cited by this paper
• ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR‐positive cancer cell lines with or without erbB2 overexpression

  2001cited by this paper
• Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

  2001cited by this paper
• Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase.

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

  2000cited by this paper
• ZD1839 ('Iressa') as an anticancer agent.

  2000cited by this paper
• A Phase I intermittent dose-escalation trial of ZD1839 (IressaTM) in Japanese patients with solid malignant tumors

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors

  2000cited by this paper
• Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.

  2000cited by this paper
• The epidermal growth factor receptor and its inhibition in cancer therapy.

  1999cited by this paper
• Tyrosine kinases in disease: overview of kinase inhibitors as therapeutic agents and current drugs in clinical trials.

  1998cited by this paper
• Optimal flexible designs in phase II clinical trials.

  1998cited by this paper
• Expression of Epidermal Growth Factor‐Related Proteins and Epidermal Growth Factor Receptor in Common Epithelial Ovarian Tumors

  1997cited by this paper
• EGFR and steroid receptors in ovarian carcinoma: comparison with prognostic parameters and outcome of patients.

  1997cited by this paper
• The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer.

  1996cited by this paper
• Epidermal growth factor-related peptides and their receptors in human malignancies.

  1995cited by this paper
• Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors.

  1995cited by this paper
• Principles and Practice of Gynecologic Oncology

  1992cited by this paper
• Principles and Practice of Gynecologic Oncology

  1992cited by this paper
• Growth factors in development, transformation, and tumorigenesis.

  1991cited by this paper
• Signal transduction by epidermal growth factor occurs through the subclass of high affinity receptors

  1989cited by this paper

• FAM49B suppresses ovarian cancer cell growth through regulating MAPK signaling.

  2025cites this paper
• SORL1-Mediated EGFR and FGFR4 Regulation Enhances Chemoresistance in Ovarian Cancer

  2025cites this paper
• Identification of Targetable EGFR Mutations in Ovarian Cancer.

  2025cites this paper
• A multiplex single-cell RNA-Seq pharmacotranscriptomics pipeline for drug discovery

  2024cites this paper
• Ovarian cancer relies on the PDGFRβ–fibronectin axis for tumorsphere formation and metastatic spread

  2023cites this paper
• Bone metastatic carcinoma with EGFR amplification and mutation: A case report and literature review

  2023cites this paper
• Loss of RBPMS in ovarian cancer compromises the efficacy of EGFR inhibitor gefitinib through activating HER2/AKT/mTOR/P70S6K signaling.

  2022cites this paper
• ERBB Signaling Pathway in Cancer Stem Cells.

  2022cites this paper
• Erlotinib or Gefitinib for the Treatment of Relapsed Platinum Pretreated NSCLC and Ovarian Cancer: a Systematic Review

  2022cites this paper
• Dacomitinib improves chemosensitivity of cisplatin-resistant human ovarian cancer cells

  2021cites this paper
• p85β alters response to EGFR inhibitor in ovarian cancer through p38 MAPK-mediated regulation of DNA repair

  2021cites this paper
• Models of ovarian cancer to test new agents

  2021cites this paper
• Phase Ib/II study of weekly topotecan and daily gefitinib in patients with platinum resistant ovarian, peritoneal, or fallopian tube cancer

  2020cites this paper
• Ovarian carcinoma: pathology review with an emphasis in their molecular characteristics.

  2020cites this paper
• Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence

  2020cites this paper
• Novel Therapeutic Approaches and Targets for Ovarian Cancer

  2019cites this paper
• Kinase Inhibitors and Ovarian Cancer

  2019cites this paper
• Design, Synthesis and Antitumor Activity of Quinazoline Derivatives Bearing 2,3-Dihydro-indole or 1,2,3,4-Tetrahydroquinoline

  2019cites this paper
• Ascitic fluid from advanced ovarian cancer patients compromises the activity of receptor tyrosine kinase inhibitors in 3D cell clusters of ovarian cancer cells.

  2018cites this paper
• Impact of Precision Medicine on Drug Repositioning and Pricing: A Too Small to Thrive Crisis

  2018cites this paper
• Epidermal growth factor receptor blockers for the treatment of ovarian cancer.

  2018cites this paper
• Epigenetic loss of heparan sulfate 3‐O‐sulfation sensitizes ovarian carcinoma to oncogenic signals and predicts prognosis

  2018cites this paper
• Human epidermal growth factor receptor targeted inhibitors for the treatment of ovarian cancer

  2018cites this paper
• EGFR Immunoexpression in Malignant Serous and Mucinous Ovarian Tumors

  2018cites this paper
• Progressing precision medicine in a world of randomized trials

  2018influential citation
• Signal Transduction and Targeted Therapy for Gynecologic Cancer

  2017cites this paper
• Targeted Therapy in Gynecological Malignancy

  2017cites this paper
• EGFR Exon 19 Deletion in Pancreatic Adenocarcinoma Responds to Erlotinib, Followed by T790M-Mediated Resistance.

  2017cites this paper
• Dasatinib + Gefitinib, a non platinum-based combination with enhanced growth inhibitory, anti-migratory and anti-invasive potency against human ovarian cancer cells

  2017cites this paper
• Xiaoaiping combined with cisplatin can inhibit proliferation and invasion and induce cell cycle arrest and apoptosis in human ovarian cancer cell lines.

  2017cites this paper
• EGFR and HER2: is there a role in ovarian cancer?

  2017cites this paper
• EGFR as a prognostic biomarker and therapeutic target in ovarian cancer: evaluation of patient cohort and literature review

  2017cites this paper
• Application of chimeric antigen receptor-engineered T cells in ovarian cancer therapy.

  2017cites this paper
• Dacomitinib, a pan-inhibitor of ErbB receptors, suppresses growth and invasive capacity of chemoresistant ovarian carcinoma cells

  2017cites this paper
• An epidermal growth factor receptor exon 19 mutation in a mucin-producing gastric cancer sample from a Chinese patient.

  2016cites this paper
• The rise of genomic profiling in ovarian cancer

  2016cites this paper
• Cheminfomatic-based Drug Discovery of Human Tyrosine Kinase Inhibitors.

  2016cites this paper
• Chemoresistance and targeted therapies in ovarian and endometrial cancers

  2016cites this paper
• Developmental Therapeutics for Gynecologic Cancers: An Overview

  2016cites this paper
• The Emerging Role of Tyrosine Kinase Inhibitors in Ovarian Cancer Treatment: A Systematic Review

  2016influential citation
• Effects of silibinin on growth and invasive properties of human ovarian carcinoma cells through suppression of heregulin/HER3 pathway

  2016cites this paper
• Current trend in translational research for treatment of ovarian cancer

  2016cites this paper
• Targeted Therapy in Ovarian Cancer

  2016cites this paper
• Targeted in vivo delivery of EGFR siRNA inhibits ovarian cancer growth and enhances drug sensitivity

  2016cites this paper
• An overview of tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer

  2016cites this paper
• Dacomitinib, a new pan-EGFR inhibitor, is effective in killing ovarian cancer cells.

  2016cites this paper
• Resistance to Tyrosine Kinase Inhibitors in Different Types of Solid Cancer

  2016cites this paper
• Predictive and prognostic molecular markers for cholangiocarcinoma in Han Chinese population.

  2015cites this paper
• Investigational therapies currently in Phase II clinical trials for the treatment of pelvic serous carcinomas

  2015cites this paper
• Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy

  2015cites this paper
• Targeting retinoblastoma binding protein 6 (RBBP6) as an anti-ovarian cancer therapeutic strategy

  2015cites this paper
• Synergistic anti-tumor effect of combined inhibition of EGFR and JAK/STAT3 pathways in human ovarian cancer

  2015cites this paper
• Mechanisms of apoptosis in ovarian cancer: The small molecule targeting

  2015cites this paper
• Maintenance chemotherapy in the management of epithelial ovarian cancer

  2015cites this paper
• Roles of epidermal growth factor receptor and its ligands in ovarian cancer

  2015cites this paper
• Antibiotic monensin synergizes with EGFR inhibitors and oxaliplatin to suppress the proliferation of human ovarian cancer cells

  2015cites this paper
• Treatment of ovarian cancer beyond chemotherapy: Are we hitting the target?

  2015cites this paper
• High-grade serous ovarian cancer cell lines exhibit heterogeneous responses to growth factor stimulation

  2015cites this paper
• Novel membrane-based targets - Therapeutic potential in gynecological cancers.

  2015cites this paper
• Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup

  2014cites this paper
• Patient-derived xenograft models in gynecologic malignancies.

  2014cites this paper
• What Are the Treatment Options for Recurrent Ovarian Cancer

  2014cites this paper
• Epidermal growth factor receptor: will it ever become a therapeutic target in ovarian cancer?

  2014cites this paper
• Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904.

  2014cites this paper
• Emerging combination therapies to overcome resistance in EGFR-driven tumors

  2014cites this paper
• Clinical outcome and prognostic markers for patients with gynecologic malignancies in phase 1 clinical trials: a single institution experience from 1999 to 2010.

  2013cites this paper
• New developments in the treatment of ovarian cancer--future perspectives.

  2013cites this paper
• Functional analysis of low-moderate risk susceptibility genes emerging from pathway based approaches and genome wide association studies in epithelial ovarian cancer

  2013cites this paper
• The potential of sunitinib as a therapy in ovarian cancer

  2013cites this paper
• Detecting EGFR alterations in clinical specimens—pitfalls and necessities

  2013cites this paper
• Bevacizumab and ovarian cancer

  2013cites this paper
• Systemische Induktionschemotherapie bei fortgeschrittenem epithelialem Ovarialkarzinom

  2013cites this paper
• Molecular Pathology of Ovarian Cancer

  2013cites this paper
• Targeting tyrosine-kinases in ovarian cancer

  2013cites this paper
• Prognostic significance of several biomarkers in epithelial ovarian cancer: a meta-analysis of published studies

  2013cites this paper
• Target Therapy in Platinum-Refractory/Resistant Ovarian Cancer: From Preclinical Findings to Current Clinical Practice

  2013cites this paper
• A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: a Gynecologic Oncology Group study.

  2013cites this paper
• Management of gynecological cancers in older women

  2013cites this paper
• Ovarian Cancer Relapse: Experimental Therapies

  2013cites this paper
• Safe and targeted anticancer therapy for ovarian cancer using a novel class of curcumin analogs

  2013cites this paper
• New Strategies in the Treatment of Ovarian Cancer: Current Clinical Perspectives and Future Potential

  2013cites this paper
• Aberrations in the epidermal growth factor receptor gene in 958 patients with diverse advanced tumors: implications for therapy.

  2013cites this paper
• Title : New Strategies in the treatment of ovarian cancer-current clinical perspectives and future potential

  2013cites this paper
• A Rational Approach to the Management of Recurrent or Persistent Ovarian Carcinoma

  2012cites this paper
• Targeting Stat3 Abrogates EGFR Inhibitor Resistance in Cancer

  2012cites this paper
• Novel antagonists of growth hormone‐releasing hormone inhibit growth and vascularization of human experimental ovarian cancers

  2012cites this paper
• Optimizing Molecular-Targeted Therapies in Ovarian Cancer: The Renewed Surge of Interest in Ovarian Cancer Biomarkers and Cell Signaling Pathways

  2012cites this paper
• Optimal first-line treatment in ovarian cancer.

  2012influential citation
• Panitumumab and Pegylated Liposomal Doxorubicin in Platinum-Resistant Epithelial Ovarian Cancer With KRAS Wild-Type: The PaLiDo Study, a Phase II Nonrandomized Multicenter Study

  2012cites this paper
• A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a gynecologic oncology group study.

  2012cites this paper
• Optimal fi rst-line treatment in ovarian cancer

  2012influential citation
• EGFR/HER-targeted therapeutics in ovarian cancer.

  2012cites this paper
• Evolution of the Gynecologic Oncology Group protocols in the treatment of epithelial ovarian cancer.

  2012cites this paper
• Anti-Epidermal Growth Factor Receptor (EGFR) Antibodies Overcome Resistance of Ovarian Cancer Cells to Targeted Therapy and Natural Cytotoxicity

  2012cites this paper
• New biologic agents for the treatment of gynecologic cancers.

  2012cites this paper
• Clinical trials and future potential of targeted therapy for ovarian cancer

  2012cites this paper
• Gefitinib (ZD1839) increases the efficacy of cisplatin in ovarian cancer cells

  2012cites this paper
• Targeting angiogenesis in gynecologic cancers.

  2012cites this paper
• Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer.

  2012cites this paper
• prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer

  2012cites this paper